Central Bank & Trust CO Vertex Pharmaceuticals Inc Transaction History
Central Bank & Trust CO
- $718 Million
- Q2 2024
A detailed history of Central Bank & Trust CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Central Bank & Trust CO holds 40 shares of VRTX stock, worth $18,212. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40
Previous 40
-0.0%
Holding current value
$18,212
Previous $16,000
12.5%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding VRTX
# of Institutions
1,706Shares Held
225MCall Options Held
1.2MPut Options Held
1.59M-
Capital World Investors Los Angeles, CA26.7MShares$12.2 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$10.5 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.7 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.34 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$3.89 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $117B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...